Genclis

Executive Summary

Genclis is a French diagnostics company leveraging its proprietary platform based on the discovery of Transcription Infidelity (TI), a mechanism causing gaps in mRNA that lead to the production of TI proteins with unique immunological properties. The company is developing a novel class of diagnostic tools targeting these TI proteins, which could enable early detection and monitoring of diseases with high unmet need, particularly in oncology and autoimmune disorders. With a Phase 3 stage lead candidate, Genclis has advanced its technology through preclinical and clinical validation, positioning itself as a pioneer in TI-based diagnostics. The platform's potential to identify disease-specific immune responses offers a differentiated approach compared to conventional biomarkers. Based in Strasbourg, the company benefits from a strong biotech ecosystem and has maintained a focused development strategy despite limited public funding.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 clinical data readout for lead diagnostic candidate65% success
• Q1 2027Regulatory submission for CE marking under IVDR70% success
• H2 2026Strategic partnership or licensing deal with major diagnostics company40% success